IDDI shareholding moving forward!

October 19, 2017

IDDI, a worldwide leader in the design, conduct and analysis of clinical trials, extends its shareholding.
SRIW – Société Régionale d’Investissement de Wallonie (a Belgian public investment company) takes 20% equity stake and IDDI management’s stake increases to 30%. This evolution is a major milestone for the company’s perennity and development.

Founded in 1991 by Marc Buyse, IDDI (International Drug Development Institute) has developed a unique expertise to optimize, conduct and analyze clinical trials for the evaluation of new drugs, and to statistically validate new biomarkers. Thanks to the combination of advanced biostatistical methodology and innovative technology, IDDI brings an unrivalled approach in the collection and management of clinical data.

Operating in the USA for more than 15 years, IDDI has opened a new office in Raleigh (North Carolina) with the aim of being even closer to its American clients.

“With SRIW on board our shareholders, IDDI group strengthens its financial structure” says Marc Buyse, who remains the main shareholder and Chief Scientific Officer of the company. “By increasing their shareholding, IDDI management commits to the perennity and the development of our group in Europe and the USA.”

About IDDI:

International Drug Development Institute (IDDI) is an expert clinical trials service provider specialized in biostatistical and integrated eClinical services for pharmaceutical and biotechnology companies in several disease areas, including oncology and ophthalmology. IDDI optimizes the clinical development of drugs, biologics and devices thanks to proven statistical expertise and operational excellence. IDDI has offices in Louvain-la-Neuve (Belgium), Boston (MA) and Raleigh (NC).